- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Intellia Therapeutics Inc (NTLA)
Intellia Therapeutics Inc stock price live, this page displays NASDAQ NTLA stock exchange data. View the NTLA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Intellia Therapeutics Inc real time stock price chart below.
What Is the Intellia Therapeutics Inc Stock Price Today?
The Intellia Therapeutics Inc stock price today is 11.29.
What Is the Stock Symbol for Intellia Therapeutics Inc?
The stock symbol for Intellia Therapeutics Inc is ""NTLA.""
What Stock Exchange Does Intellia Therapeutics Inc Trade On?
Intellia Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Intellia Therapeutics Inc a Good Stock to Buy?
Determining whether Intellia Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NTLA quote. (ISIN: US45826J1051)
What Is the Intellia Therapeutics Inc Stock Price Today?
The Intellia Therapeutics Inc stock price today is 11.29.
What Is the Stock Symbol for Intellia Therapeutics Inc?
The stock symbol for Intellia Therapeutics Inc is ""NTLA.""
What Stock Exchange Does Intellia Therapeutics Inc Trade On?
Intellia Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Intellia Therapeutics Inc a Good Stock to Buy?
Determining whether Intellia Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NTLA quote. (ISIN: US45826J1051)
Currency in USD
11.29
-0.10(-0.83%)
Real-time Data·
Fair Value
An estimate of a Intellia Therapeutics Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.25
11.62
52 wk Range
5.90
23.76
NTLA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NTLA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Intellia Therapeutics Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.2511.62
52 wk Range
5.9023.76
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NTLA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Intellia Therapeutics Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
33.54
Upside
+197.06%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
11 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Intellia Therapeutics Inc Company Profile
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Intellia Therapeutics Inc SWOT Analysis
Gene Editing Pionee | Intellia Therapeutics leads CRISPR/Cas9 innovation with promising clinical trials for hereditary angioedema and transthyretin amyloidosis, showcasing potential for revolutionary treatments |
Financial Fortitude | With $707.1 million in cash and reduced burn rate, Intellia's runway extends to 2028, positioning it strongly for upcoming pivotal trial milestones and potential commercialization |
Market Disruption | Explore how Intellia's one-time gene editing treatments could capture substantial market share in multi-billion dollar markets, challenging current repeated-administration therapies |
Analyst Outlook | Consensus leans bullish with price targets ranging from $7 to $106, reflecting the high-risk, high-reward nature of Intellia's innovative pipeline and market potential |
Intellia Therapeutics Inc Earnings Call Summary for Q2/2025
- Intellia beats Q2 2025 forecasts: EPS of -0.98 vs -1.03 expected, revenue of $14.24M vs $11.99M anticipated
- Strong cash position of $630.5M as of June 30, 2025, supporting operations into 2027
- Advancements in gene-editing treatments for HAE and ATTR amyloidosis; targeting 3 product launches by 2030
- Stock fell 2.99% to $11.37 despite earnings beat; pre-market trading showed slight recovery of 2.02%
- CEO highlights unique market position; CMO emphasizes goal of zero HAE attacks without medication
Last Updated: 07/08/2025, 17:14
Read Full TranscriptCompare NTLA to Peers and Sector
Metrics to compare | NTLA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNTLAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.5x | 2.3x | −0.6x | |
PEG Ratio | −0.18 | 0.00 | 0.00 | |
Price/Book | 1.7x | 2.5x | 2.6x | |
Price / LTM Sales | 22.9x | 6.0x | 3.3x | |
Upside (Analyst Target) | 119.7% | 298.4% | 39.0% | |
Fair Value Upside | Unlock | 23.6% | 4.9% | Unlock |
Analyst Ratings
21 Buy
6 Hold
1 Sell
Ratings:
28 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 33.54
(+197.06% Upside)
Earnings
Latest Release
Aug 07, 2025
EPS / Forecast
-0.98 / -1.03
Revenue / Forecast
14.24M / 11.99M
People Also Watch
FAQ
What Stock Exchange Does Intellia Therapeutics Inc Trade On?
Intellia Therapeutics Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Intellia Therapeutics Inc?
The stock symbol for Intellia Therapeutics Inc is "NTLA."
What Is the Intellia Therapeutics Inc Market Cap?
As of today, Intellia Therapeutics Inc market cap is 1.21B.
What Is Intellia Therapeutics Inc's Earnings Per Share (TTM)?
The Intellia Therapeutics Inc EPS (TTM) is -4.68.
When Is the Next Intellia Therapeutics Inc Earnings Date?
Intellia Therapeutics Inc will release its next earnings report on 05 Nov 2025.
From a Technical Analysis Perspective, Is NTLA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Intellia Therapeutics Inc Stock Split?
Intellia Therapeutics Inc has split 0 times.
How Many Employees Does Intellia Therapeutics Inc Have?
Intellia Therapeutics Inc has 403 employees.
What is the current trading status of Intellia Therapeutics Inc (NTLA)?
As of 26 Aug 2025, Intellia Therapeutics Inc (NTLA) is trading at a price of 11.29, with a previous close of 11.38. The stock has fluctuated within a day range of 11.25 to 11.62, while its 52-week range spans from 5.90 to 23.76.
What Is Intellia Therapeutics Inc (NTLA) Price Target According to Analysts?
The average 12-month price target for Intellia Therapeutics Inc is USD33.53846, with a high estimate of USD106 and a low estimate of USD7. 21 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +197.06% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.